| Literature DB >> 17720266 |
Samuel Bral1, Hilde Van Parijs, Guy Soete, Nadine Linthout, Lutgard Van Moorter, Dirk Verellen, Guy Storme.
Abstract
We treated 36 cases of stage I/II non-small cell lung cancer in inoperable patients. Treatments were planned to a total isocenter dose of 60Gy (8x7.5Gy) based on a dynamic field shaping arc, employing one arc to span as much area as possible and if needed additional weighted segments. The 2 year infield progression free probability is 65%. Disease-specific survival is 75% at 2 years. No patients experienced grade 3-4 toxicity.Entities:
Mesh：
Year: 2007 PMID： 17720266 DOI： 10.1016/j.radonc.2007.07.010
Source DB: PubMed Journal: Radiother Oncol ISSN： 0167-8140 Impact factor: 6.280